News - Page 150 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

Post published:September 14, 2021
Post category:Press Release

Read more about the article Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

Post published:September 14, 2021
Post category:Press Release

Read more about the article Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay

Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay

Post published:September 14, 2021
Post category:Press Release

Read more about the article Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline

Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline

Post published:September 14, 2021
Post category:Press Release

Read more about the article COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

Post published:September 14, 2021
Post category:Press Release

Read more about the article NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets

NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets

Post published:September 13, 2021
Post category:Press Release

Read more about the article PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

Post published:September 13, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: Proliferation of Psilocybin-Related Drug Development; Biden-Harris Administration Aims to Reduce Barriers to Schedule I Research

Psychedelic Bulletin: Proliferation of Psilocybin-Related Drug Development; Biden-Harris Administration Aims to Reduce Barriers to Schedule I Research

Post published:September 10, 2021
Post category:Psychedelic Bulletin

Read more about the article Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Post published:September 10, 2021
Post category:Press Release

Read more about the article MYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offering

MYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offering

Post published:September 9, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.